J&J's Icotyde Pill Revolutionizes Psoriasis Treatment

A License to Heal Not to Inject

Right let's cut to the chase. The Yanks at the FDA have given the green light to Johnson & Johnson's Icotyde – a pill a simple once daily pill for psoriasis. It appears some blokes are frightened of needles. Well I’ve faced down Oddjob's steel rimmed bowler; a little pinprick never bothered me. But for those who prefer their medicine shaken not injected this could be just the ticket.

From Topicals to Tablets The New Order

Word is this Icotyde is gunning to be the go to between your standard creams and those rather pricey injectable biologics. They are saying that AI Titans Clash Anthropic Secures Massive Funding to Challenge OpenAI aren't the only thing shaking up established markets drug companies are too with more advanced medicines and pills instead of needles. J&J seems confident that it can slot neatly into the market especially for those who haven't fancied moving beyond the ointment. Naturally time will tell.

Targeting IL 23 A Familiar Foe

Apparently this Icotyde takes aim at the same IL 23 receptor as some of the big name injections like J&J's own Tremfya and AbbVie's Skyrizi. So it’s like facing off against a known enemy but with a different weapon. And while I am more partial to my Walther PPK perhaps an oral medication will have its merits in this arena.

Revolutionary or Just a Shot in the Arm for J&J

Jennifer Taubert from J&J is calling it a 'game changer'. Strong words. But let's be honest if it gets those needle shy patients on board and keeps the skin looking smoother than a freshly polished Aston Martin then maybe just maybe she's onto something. As for me I am always on the lookout for game changers.

The Price of Beauty and Healthcare

The million dollar question as always (or in this case the $100,000 question which is how much those rival shots cost per year) is the price. J&J is keeping mum for now only promising to help with the bills. Let's hope it doesn't end up costing more than a bespoke suit on Savile Row.

Beyond Psoriasis The Expanding Empire

J&J isn't stopping with just psoriasis. They're testing Icotyde for psoriatic arthritis ulcerative colitis and Crohn's disease. Sounds like they are planning a global takeover of the autoimmune market. And with projected peak sales of over $5 billion they might just pull it off. Although one hopes they will use their vast resources to protect their IP and systems like any good organisation should. After all 'you only live twice' and that includes the products which help you stay alive.